» Articles » PMID: 4378110

Studies of the Immunogenicity, Communicability and Genetic Stability of Oral Poliovaccine Administered During the Winter

Overview
Journal Am J Epidemiol
Specialty Public Health
Date 1967 Jul 1
PMID 4378110
Citations 44
Authors
Affiliations
Soon will be listed here.
Citing Articles

Is it time to switch to a formulation other than the live attenuated poliovirus vaccine to prevent poliomyelitis?.

Devaux C, Pontarotti P, Levasseur A, Colson P, Raoult D Front Public Health. 2024; 11:1284337.

PMID: 38259741 PMC: 10801389. DOI: 10.3389/fpubh.2023.1284337.


Impact of Supplementary Immunization Activities using Novel Oral Polio Vaccine Type 2 during a Large outbreak of Circulating Vaccine-Derived Poliovirus in Nigeria.

Voorman A, Lyons H, Shuaib F, Adamu U, Korir C, Erbeto T J Infect Dis. 2023; 229(3):805-812.

PMID: 37357964 PMC: 10938209. DOI: 10.1093/infdis/jiad222.


Immunogenicity of novel oral poliovirus vaccine type 2 administered concomitantly with bivalent oral poliovirus vaccine: an open-label, non-inferiority, randomised, controlled trial.

Wilkinson A, Zaman K, Hoque M, Estivariz C, Burns C, Konopka-Anstadt J Lancet Infect Dis. 2023; 23(9):1062-1071.

PMID: 37178706 PMC: 10503264. DOI: 10.1016/S1473-3099(23)00139-1.


Use of Oral Polio Vaccine and the Global Incidence of Mother-to-Child Human Immunodeficiency Virus Transmission.

Habibzadeh F, Yadollahie M, Simi A Front Public Health. 2022; 10:878298.

PMID: 35812500 PMC: 9261940. DOI: 10.3389/fpubh.2022.878298.


Review of use of inactivated poliovirus vaccine in campaigns to control type 2 circulating vaccine derived poliovirus (cVDPV) outbreaks.

Estivariz C, Kovacs S, Mach O Vaccine. 2022; 41 Suppl 1:A113-A121.

PMID: 35365341 PMC: 10389290. DOI: 10.1016/j.vaccine.2022.03.027.